Related Experiment Video

Updated: Aug 29, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine

Rachel Schiff1, Suleiman A Massarweh, Jiang Shou

  • 1Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. rschiff@breastcenter.tmc.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|January 22, 2004
PubMed

Insights

Endocrine therapy remains crucial for estrogen receptor-positive breast cancer. Combining it with targeted therapies may overcome resistance, improving treatment outcomes.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Endocrine therapy is a cornerstone treatment for estrogen receptor (ER)-positive breast tumors.
  • Tumor resistance, both de novo and acquired, significantly limits the efficacy of endocrine therapy.
  • Complex cross-talk between ER signaling and growth factor/kinase pathways contributes to resistance.

Purpose of the Study:

  • To explore the molecular mechanisms underlying endocrine resistance in ER-positive breast cancer.
  • To evaluate strategies for overcoming endocrine resistance, particularly through combination therapies.
  • To discuss future challenges and open questions in molecular ER biology related to endocrine therapy.

Main Methods:

  • Review of recent discoveries in ER signaling and its interaction with kinase pathways.
  • Analysis of genomic and nongenomic ER activities contributing to resistance.
  • Discussion of combining endocrine therapy (e.g., tamoxifen) with targeted inhibitors.

Main Results:

  • ER signaling complexity and cross-talk with other pathways are key factors in endocrine resistance.
  • Targeted therapies against pathways like EGFR/HER-2 show potential when integrated with endocrine therapy.
  • Combination strategies offer a promising approach to circumvent both de novo and acquired resistance.

Conclusions:

  • Understanding the intricate molecular biology of ER is vital for improving endocrine therapy efficacy.
  • Combining endocrine therapy with targeted inhibitors is a viable strategy to overcome resistance.
  • Further research is needed to address open questions and challenges in this dynamic field.

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion06:36

A Modified In vitro Invasion Assay to Determine the Potential Role of Hormones, Cytokines and/or Growth Factors in Mediating Cancer Cell Invasion

Published on: April 24, 2015

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...